Screener
Bio-Rad Laboratories BIO Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| LIABILITIES AND STOCKHOLDERS’ EQUITY | March 31, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $133.1 | $129.0 |
| Accrued payroll and employee benefits | 148.4 | 172.3 |
| Current maturities of long-term debt and notes payable | 400.5 | 1.3 |
| Income and other taxes payable | 44.9 | 36.6 |
| Current operating lease liabilities | 36.2 | 36.1 |
| Other current liabilities | 153.9 | 141.7 |
| Total current liabilities | 917.0 | 517.0 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's accrued manufacturing costs?
- Bio-Rad Laboratories (BIO) reported accrued manufacturing costs of $148.4M in Q1 2026.
- How has Bio-Rad Laboratories's accrued manufacturing costs changed year-over-year?
- Bio-Rad Laboratories's accrued manufacturing costs decreased by 5.7% year-over-year, from $157.4M to $148.4M.
- What is the long-term trend for Bio-Rad Laboratories's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's accrued manufacturing costs has grown at a -5.0% compound annual growth rate (CAGR), from $222.88M to $172.3M.
Ask your AI about Bio-Rad Laboratories's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude